Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
Introduction: Imatinib Mesylate is a selective inhibitor of TK and is considered now to be the frontline therapeutic agent during the chronic phase of CML. We have evaluated the efficacy of it on children with chronic-phase of CML.
Patients and Methods: In a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of CML. Seven patients who were in the early chronic-phase and seven who were in the late chronic-phase suffered from hematological relapse while being treated with conventional therapy. All of them had positive BCR-ABL in peripheral blood and bone marrow. Glivec was given as an oral dose of 300mg/m2/d. Then, regular monitoring was done for hematological and cytogenetic response, toxic effects, disease progression and survival.
Results: All seven patients with newly- diagnosed CML and five previously treated patients attained complete and sustained hematological and cytogenetic remission in a follow-up period over 2 to 30 months (the mean was 22.5). One patient was taken off study because of drug intolerance. One patient in each group relapsed after initial response and died from progressive disease. Overall survival was 86%. No major side effects were noted and there was no drug- related mortality.
Conclusion: Glivec has proved to be effective in inducing prolonged complete hematological and cytogenetic remission in newly- diagnosed as well as previously treated children with CML. One major problem is prolonged, unlimited and continued therapy which results in poor compliance as time goes by. In addition, in developing countries, high cost and suboptimal accessibility would make its routine use quite difficult.
Shimoni A, Kroger N, Zander AR, et al. Imatinib Mesylate (STI571) in Preparation for Allogeneic Hematopoietic Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients with Philadelphia-positive Acute Leukemias; Leukemia, 2003; 17 (2): 290-7.
Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia; N Engl Med, 2002, 346 (9): 645-52.
Melo JV, Hughes TP, Apperley JF. Chronic Myeloid Leukemia. The American Society of Hematology; December 6-9, 2003; San Diego, California. Audio Cassette Catalog. 1. http://www.hematology.org/images/pdf.
Druker BJ, Sawyers CL, Kantarjian H, et al: Efficacy and Safety of a Specific Inhibitor of the bcr-abl Tyrosine Kinase in Chronic Myeloid Leukemia; N Engl Med, 2001, 344 (14), 1038-42.
Druker BJ, Tamura S, Buchdunger E, et al. Activity of a Specific Inhibitor of the bcr-abl Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome; N Engl Med, 2001, 344: 1038-1042.
Cwynarski K, Roberts IAG, Iacobelli S, et al. Stem Cell Transplantation for Chronic Myeloid Leukemia in Children; Blood, 2003, 102 (4): 1224-1231.
John Barrett. Allogenic Stem Cell Transplantation for Chronic Myeloid Leukemia; Seminar in Hematology, 2003; 40 (1): 59-71.
Pulshiper MA. Treatment of CML in Pediatric Patients: Should Imatinib Mesylate (STI-571, Gleevec) or Allogeneic Hematopoietic Cell Transplant be Front-line Therapy? Pediatr Blood Cancer, 2004; 43: 523-533.
Baccarani M, Russo D, Rosti G, et al. Interferon-Alfa for Chronic Myeloid Leukemia; Seminar in Hematology, 2003; 40 (1): 22-33.
Pizzo PA & Poplack DG. Principles and Practice of Pediatric Oncology. 5th ed.: Lippincott Williams & Wilkins; 2005.
Hahn EA, Glendenning GA, Sorensen MV, et al: Quality of Life in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib versus Interferon Alfa plus Low-dose Cytarabine: Results from the IRIS Study; Journal of Clinical Oncology, 2003, 21(11): 2138-2146.
Alois Gratwohl. Prognostic Factors in Chronic Myeloid Leukemia: Allografting; Seminar in Hematology, 2003; 40(1): 13-21.
Druker BJ, Sawyers CL, Deville RC, et al. Chronic Myelogenous Leukemia. Hematology, American Society of Hematology Education Program Book, 2001; 87-112
Deininger MWN, O'Brien SG, Ford JM, et al. Practical Management of Patients with Chronic Myeloid Leukemia Receiving Imatinib. Journal of Clinical Oncology, 2003; 21(8): 1637-1647.
Jorge Cortes, Francis Giles, Susan O'Brien, et al: Result of high dose Imatinib Mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferone-α; Blood, 2003, 102(1): 83-6.
O'Brien SG, Guilhot F, Larson RA, et al: Imatinib Compared with Interferon and Low-dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia; N Engl J Med, 2003; 348(11): 994-1004.
Garcia-Manero G, Faderi S, O'Brien S, et al. Chronic Myelogenous Leukemia: A Review and Update of Therapeutic Strategies.
Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib Mesylate Therapy Improves Survival in Patients with Newly Diagnosed Philadelphia Chromosome-positive Chronic Myelogenous Leukemia in Chronic Phase; Cancer, 2003; 98(12): 2636-42.
|Issue||Vol 3, No 3 (2009)|
|Imatinib Mesylate CML Tyrosine Kinase|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|